2-氨基-3-氟-5-氯吡啶 | 246847-98-3

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氨基-3-氟-5-氯吡啶
• 中文别名: 2-氨基-5-氯-3-氟砒啶；2-氨基-5-氯-3-氟吡啶
• 英文名称: 5-chloro-3-fluoropyridin-2-amine
• 英文别名: 2-amino-5-chloro-3-fluoropyridine；2-amino-3-fluoro-5-chloropyridine
• CAS: 246847-98-3
• 化学式: C₅H₄ClFN₂
• 分子量: 146.552
• InChiKey: FPUPPVDVOFJSEP-UHFFFAOYSA-N

物化性质

• 熔点：
  91-95 °C
• 沸点：
  195.9±35.0 °C(Predicted)
• 密度：
  1.449±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi,T
• 安全说明：
  S36/37,S38,S45,S61,S63
• 危险类别码：
  R23/24/25,R50
• WGK Germany：
  2
• 海关编码：
  2933399090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H317,H319
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Amino-5-chloro-3-fluoropyridine
Synonyms: 5-Chloro-3-fluoropyridin-2-amine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
H311: Toxic in contact with skin
H319: Causes serious eye irritation
Toxic if inhaled
H331:
H400: Very toxic to aquatic life
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P273: Avoid release to the environment
P280: Wear protective gloves/protective clothing/eye protection/face protection
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P311: Call a POISON CENTER or doctor/physician

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Amino-5-chloro-3-fluoropyridine
CAS number: 246847-98-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C5H4ClFN2
Molecular weight: 146.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN2811 Class: 6.1 Packing group: III
Proper shipping name: TOXIC SOLIDS, ORGANIC, N.O.S. (2-Amino-5-chloro-3-fluoropyridine)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基-3-氟-5-氯吡啶 在 ammonium hydroxide 、 palladium on activated charcoal 、 氢气 作用下， 以 甲醇 为溶剂， 以90.2%的产率得到2-氨基-3-氟吡啶
  参考文献：
  名称：

  一种2-氨基-3-氟吡啶的制备工艺

  摘要：

  本发明公开了一种2‑氨基‑3‑氟吡啶的制备工艺。以2,3‑二氟‑5‑氯吡啶为原料，与氨水发生氨化反应，再经还原反应得到2‑氨基‑3‑氟吡啶。本发明反应步骤少，操作简单，原料价廉易得，后处理简便易行，产率高，总收率可达77.5%。并且适合大规模制备。

  公开号：

  CN105669539B
• 作为产物：
  描述：

  2,3-二氟-5-氯吡啶 在 氨 作用下， 以 水 为溶剂， 反应 1.0h， 以76%的产率得到2-氨基-3-氟-5-氯吡啶
  参考文献：
  名称：

  Certain Chemical Entities, Compositions, and Methods

  摘要：

  提供了某些化学实体和使用方法，用于调节骨骼肌肌球蛋白、骨骼肌肌动蛋白、骨骼肌肌肽肌动蛋白、骨骼肌肌钙蛋白C、骨骼肌肌钙蛋白I、骨骼肌肌钙蛋白T和骨骼肌，包括其片段和同工异构体，以及骨骼肌肌节，以及在治疗肌无力和/或消瘦症、作为康复或锻炼计划的一部分，或在治疗虚弱、脊髓灰质炎后综合症、肥胖、肌少症、消耗综合症、肌肉痉挛和其他适应症中的使用方法。

  公开号：

  US20080242695A1

文献信息

• Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19
  作者：Aurélie Mallinger、Kai Schiemann、Christian Rink、Frank Stieber、Michel Calderini、Simon Crumpler、Mark Stubbs、Olajumoke Adeniji-Popoola、Oliver Poeschke、Michael Busch、Paul Czodrowski、Djordje Musil、Daniel Schwarz、Maria-Jesus Ortiz-Ruiz、Richard Schneider、Ching Thai、Melanie Valenti、Alexis de Haven Brandon、Rosemary Burke、Paul Workman、Trevor Dale、Dirk Wienke、Paul A. Clarke、Christina Esdar、Florence I. Raynaud、Suzanne A. Eccles、Felix Rohdich、Julian Blagg

  DOI：10.1021/acs.jmedchem.5b01685

  日期：2016.2.11

  complex-associated cyclin-dependent kinase CDK8 has been implicated in human disease, particularly in colorectal cancer where it has been reported as a putative oncogene. Here we report the discovery of 109 (CCT251921), a potent, selective, and orally bioavailable inhibitor of CDK8 with equipotent affinity for CDK19. We describe a structure-based design approach leading to the discovery of a 3,4,5-trisubstituted-2-aminopyridine

  介体复合物相关的细胞周期蛋白依赖性激酶 CDK8 与人类疾病有关，特别是在结肠直肠癌中，据报道它是一种推定的癌基因。在这里，我们报告了109 (CCT251921) 的发现，它是一种有效的、选择性的和口服生物可利用的 CDK8 抑制剂，对 CDK19 具有等效的亲和力。我们描述了一种基于结构的设计方法，导致发现了 3,4,5-三取代-2-氨基吡啶系列，并介绍了物理化学性质分析的应用，以成功降低体内代谢清除率，最大限度地减少转运蛋白介导的胆汁消除，同时保持可接受的水溶性。化合物109提供了体外生化、药代动力学和物理化学性质的最佳折衷，并适用于发展为癌症动物模型。
• [EN] INHIBITORS OF KRAS G12C MUTANT PROTEINS<br/>[FR] INHIBITEURS DE PROTÉINES MUTANTES KRAS G12C
  申请人：ARAXES PHARMA LLC

  公开号：WO2017058915A1

  公开（公告）日：2017-04-06

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein A, B R1, R2a, R2b, R3a, R3b, R4a, R4b, G1, G2, m1, m2, L1, L2 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  提供了作为G12C突变KRAS蛋白抑制剂活性的化合物。这些化合物具有以下结构（I）：或其药用可接受的盐、互变异构体、立体异构体或前药，其中A、B、R1、R2a、R2b、R3a、R3b、R4a、R4b、G1、G2、m1、m2、L1、L2和E如本文所定义。还提供了与制备和使用这些化合物相关的方法，包括包含这些化合物的药物组合物以及调节G12C突变KRAS蛋白活性的方法，用于治疗癌症等疾病。
• [EN] INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE LA PROTÉINE KINASE I INTERAGISSANT AVEC LE RÉCEPTEUR POUR LE TRAITEMENT D'UNE MALADIE
  申请人：UNIV TEXAS

  公开号：WO2021173917A1

  公开（公告）日：2021-09-02

  Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.

  公开了抑制RIPK1的化合物，药物组合物以及治疗RIPK1介导的疾病的方法，如神经退行性疾病，炎症性疾病和癌症。
• INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
  申请人：Shire Human Genetic Therapies, Inc.

  公开号：US20190284182A1

  公开（公告）日：2019-09-19

  The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

  本发明提供了作为血浆激肽酶抑制剂并具有相同理想特性的化合物和组合物。
• [EN] (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES<br/>[FR] (AZA)INDOLE, BENZOTHIOPHÈNE ET BENZOFURAN-3-SULFONAMIDES
  申请人：UCB PHARMA GMBH

  公开号：WO2018122232A1

  公开（公告）日：2018-07-05

  Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.

  揭示了具有GPR17调节特性的磺胺类化合物，可用于治疗或预防各种中枢神经系统和其他疾病，特别是用于预防和治疗髓鞘疾病或紊乱。